Understanding BUD Dates in Compounding: Why 12 Months Matters

If you order compounded medications for your practice, beyond-use dating (BUD) is one of the most operationally significant factors you need to understand. Short BUD dates create waste, cash flow problems, and supply chain headaches. Extended BUD dates — up to 12 months — change the economics of running a compounding-dependent practice.

This post explains what BUD dates are, how they are determined under USP <795> and USP <797>, and why the difference between a 30-day and a 12-month BUD date matters enormously for your practice.

A beyond-use date (BUD) is the date after which a compounded preparation should not be used. It is assigned by the compounding pharmacy based on the specific formulation, storage conditions, and available stability data — not by the FDA. Unlike the expiration date on a manufactured drug, a BUD is the compounder's own determination of how long the preparation remains stable, sterile (if applicable), and potent under specified storage conditions.

BUD dates are not arbitrary. They are governed by USP standards and, when extended beyond defaults, must be supported by documented stability testing. A pharmacy that cannot show you the data behind its BUD claims is a pharmacy you should scrutinize carefully.

BUD dates for compounded preparations are governed by three USP chapters: <795> (non-sterile), <797> (sterile), and <800> (hazardous drugs). Each chapter sets default BUD limits based on preparation type and storage conditions. Compounders can assign longer BUD dates only when they have supporting stability data from appropriate testing — the default limits are floors, not ceilings, for facilities that do the work.

The three governing chapters are:

• USP <795> — Non-sterile preparations (oral solutions, topicals, capsules)
• USP <797> — Sterile preparations (injectables, ophthalmic solutions)
• USP <800> — Hazardous drugs (chemotherapy agents, certain hormones)

Most compounded GLPs and peptides fall under USP <797> as sterile injectables. Non-sterile oral or topical formulations fall under USP <795>.

These are default limits. With stability testing data, compounders can extend BUD dates beyond these defaults.

Category 2 preparations with full stability data and appropriate testing can qualify for BUD dates up to 12 months. This is the pathway used by 503B outsourcing facilities operating under cGMP standards.

Twelve-month BUD dates require four things: documented stability testing, a formulation designed for long-term stability, controlled storage conditions, and — for 503B facilities — cGMP manufacturing processes. Most 503A pharmacies operating under default USP limits cannot offer extended BUD dates because they have not conducted the stability studies required to support them. 503B outsourcing facilities are better positioned because their manufacturing infrastructure is built for it.

The four requirements for extended BUD dates are:

1. Stability testing — The compounder must conduct or reference stability studies demonstrating the preparation remains within specification for the claimed BUD period. This includes potency, sterility, pH, and particulate testing at defined intervals.
2. Appropriate formulation — The formulation must be designed for stability: correct pH, appropriate preservatives, compatible packaging materials, and a vehicle that does not degrade the active ingredient over time.
3. Controlled storage conditions — Refrigeration (2–8°C) or freezing (−20°C or below) as appropriate to the preparation. Temperature excursions during shipping can void a BUD date.
4. cGMP manufacturing (503B facilities) — Consistent, validated manufacturing processes with environmental monitoring, equipment qualification, and batch records that support extended dating claims.

503B outsourcing facilities operating under FDA cGMP oversight are generally the only facilities that can reliably deliver 12-month BUD dates on sterile injectables like compounded semaglutide and tirzepatide.

Short BUD dates force frequent small orders, increase waste, and create supply chain fragility. Extended BUD dates — up to 12 months — allow larger order quantities, lower per-unit cost, and buffer stock that protects patient continuity. For practices ordering compounded GLPs or peptides at any meaningful volume, BUD dates are a direct driver of practice economics.

Here is how BUD dates affect each dimension of your practice:

Short BUD dates force you to order frequently in small quantities. This increases your administrative burden, your shipping costs, and your risk of running out of product when you need it. With 12-month BUD dates, you can order in larger quantities, reduce reorder frequency, and maintain a buffer stock that protects your patients from supply disruptions.

If you order more product than you use before the BUD date, you are throwing money away. Short BUD dates make this problem worse — a 30-day BUD on a slow week means product you cannot use. Extended BUD dates give you the flexibility to order at the right volume without waste risk.

Ordering in larger quantities at longer intervals is generally more cash-flow efficient than frequent small orders. Extended BUD dates enable a more favorable ordering cadence and reduce the working capital tied up in frequent reorders.

Supply disruptions are one of the most common reasons patients discontinue GLP-1 protocols. A practice with adequate buffer stock — enabled by extended BUD dates — can maintain patient continuity even when supply chain disruptions occur. Patients who run out of medication are patients who drop off.

For practices ordering at scale ($10,000+ per order), extended BUD dates are not optional — they are essential. You cannot practically order at that volume if the product expires in 30 days. The math does not work.

A BUD date is assigned by the compounding pharmacy based on its own stability data and USP standards. An expiration date is assigned by the manufacturer of an FDA-approved finished drug product based on formal stability studies submitted to the FDA. They are not the same thing and should not be treated as equivalent. Compounded preparations do not have FDA-approved expiration dates — they have BUD dates, which carry different regulatory weight and are the compounder's responsibility to support.

This distinction matters when patients ask whether compounded medications are "as good as" brand-name products. The answer involves more than just the active ingredient — it includes the stability framework behind the dating.

Ask every compounding supplier these five questions before placing a significant order: What BUD dates do you assign? What stability data supports them? Are they based on USP defaults or extended testing? What storage conditions are required? And do you provide storage instructions with each shipment? A supplier that cannot answer these questions clearly is a supplier you should think twice about.

The five questions:

1. What BUD dates do you assign to your compounded GLP-1 and peptide products? Get the specific number — not a range, not "it depends."
2. Do you have stability data supporting those BUD dates? Ask to see a summary. Legitimate facilities have it.
3. Are your BUD dates based on USP defaults or extended stability testing? Default BUD dates require no testing. Extended dates do.
4. What storage conditions are required to maintain the BUD date? Temperature, light exposure, and container type all matter.
5. Do you provide storage instructions and COAs with each shipment? Certificate of Analysis documentation should accompany every lot.

A supplier that cannot answer these questions clearly — or deflects with vague assurances — is not a supplier you want managing your practice's medication supply.

MedClinic Partners works exclusively with 503B outsourcing facilities and cGMP-compliant 503A pharmacies that provide documented stability data for their BUD claims. We offer up to 12-month BUD dates on select compounded preparations — not as a marketing claim, but as a function of the manufacturing standards and stability testing programs of our pharmacy network. Extended BUD dates are one of the primary reasons high-volume practices choose us over suppliers who can only offer 30 to 90-day dating.

Every shipment through the MedClinic Partners portal includes:

• Certificate of Analysis (COA) for each lot
• Storage instructions specific to the preparation
• BUD date documentation tied to the stability data on file
• Cold-chain packaging validated for overnight transit

If you are currently ordering from a supplier that cannot provide these documents, or whose BUD dates are based on USP defaults rather than stability testing, request portal access to see what extended-BUD supply looks like in practice.

For licensed medical providers only. BUD date information is general in nature and reflects USP standards and general compounding practice as of the publication date. Specific BUD dates for individual preparations depend on formulation, storage conditions, and the stability data on file at the compounding facility. This post does not constitute legal or regulatory advice.